ALK7 antagonists and uses thereof
US12024563B2 · kind B2 · utility
0Cited by
10References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 19, 2021 |
| Grant date | Jul 2, 2024 |
| Priority date | — |
| Expiry date | Oct 19, 2041 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.